Neuron-specific enolase--a serum tumour marker in seminoma?

por Fosså, S. D., Klepp, O., Paus, E.
Publicado 1992

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.

por Fosså, S. D., Waehre, H., Paus, E.
Publicado 1992

89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.

por Fosså, S. D., Paus, E., Lochoff, M., Backe, S. M., Aas, M.
Publicado 1992

Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.

por Hernes, E. H., Fosså, S. D., Vaage, S., Ogreid, P., Heilo, A., Paus, E.
Publicado 1997

Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer

por Fosså, A, Siebert, R, Aasheim, H-C, Mælandsmo, G M, Berner, A, Fosså, S D, Paus, E, Smeland, E B, Gaudernack, G
Publicado 2000

Candidate epitopes for measurement of hCG and related molecules: the second ISOBM TD-7 workshop

por Berger, P., Paus, E., Hemken, P. M., Sturgeon, C., Stewart, W. W., Skinner, J. P., Harwick, L. C., Saldana, S. C., Ramsay, C. S., Rupprecht, K. R., Olsen, K. H., Bidart, J.-M., Stenman, U.-H.
Publicado 2013